Early-onset GI cancers diagnosed before age 50 are rising at alarming rates worldwide, underscoring the need for enhanced ...

British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, ...

In letters to the companies released on Thursday, Trump said he expected them to deliver on a series of measures to lower ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...

The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.

GlaxoSmithKline ( ($GSK) ) has released its Q2 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.

The U.S., Haleon's biggest market, has been a drag on performance. Consumer confidence remains weak and Haleon was also hit ...

A single dose of RSVPreF3 OA offered protection against RSV-related lower respiratory tract disease across three RSV seasons ...

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...